Skip to main content
IXICO PLC logo

IXICO PLC — Investor Relations & Filings

Ticker · IXI ISIN · GB00BFXR4C20 LEI · 2138005M1F59O6HWSA97 IL Professional, scientific and technical activities
Open in API
Filings indexed 354 across all filing types
Latest filing 2022-11-21 Report Publication Anno…
Country GB United Kingdom
Listing IL IXI

About IXICO PLC

https://www.ixico.com/

IXICO PLC is a clinical research and data analytics company specializing in neuroscience. It provides neuroimaging and digital biomarker analytics to biopharmaceutical firms conducting clinical trials for neurological disorders. The company utilizes its proprietary, AI-driven technology platform to manage and analyze complex imaging and digital health data. This platform deploys disease-specific algorithms to generate reliable clinical data and precision insights, aiming to accelerate research and development decision-making, de-risk clinical studies, and support the advancement of new therapies for conditions such as Alzheimer's and Huntington's disease.

Recent filings

Filing Released Lang Actions
Notice of Results and Investor Presentation
Report Publication Announcement Classification · 1% confidence The document is a short announcement (4017 characters) released via RNS (London Stock Exchange news service). The title is "Notice of Results and Investor Presentation." It explicitly states that the company "confirms that it will issue its Full Year Results for the year to 30 September 2022 on Wednesday 7th December 2022" and announces a live investor presentation for those results. Since the document itself is not the full results (10-K or IR) but rather an announcement about the *timing* and *format* of the results release and an associated presentation, it fits the definition of a Report Publication Announcement (RPA). It is announcing the publication of future reports/events.
2022-11-21 English
Trading Update
Earnings Release Classification · 1% confidence The document is titled 'Trading Update for year ended 30 September 2022' and provides preliminary financial highlights (revenue, order book, cash, EBITDA) for the fiscal year, explicitly stating that the company 'intends to announce its audited results for the year ended 30 September 2022 in early December 2022.' This structure—a brief update on key figures before the full report release—is characteristic of an Earnings Release (ER). Furthermore, the document is distributed via RNS, which often carries these preliminary announcements. Since it is not the full audited report (10-K) or the comprehensive interim report (IR), ER is the most appropriate classification for this pre-results summary. FY 2022
2022-10-25 English
HD-IH Consortium
Regulatory Filings Classification · 1% confidence The document is identified by the RNS Number '1514A' and is dated September 21, 2022. It announces a new consortium (HD-IH) formed by IXICO and other entities to analyze Huntington's disease imaging data using AI. The text explicitly states, 'This information is being released on various platforms including the Company's website,' and concludes with a disclaimer stating, 'Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature.' This structure—a press release distributed via the RNS system but explicitly marked as non-regulatory news (Reach)—indicates a general corporate announcement that does not fit the specific categories like ER, 10-K, or DIV. Since it is a general, non-regulatory announcement that doesn't fit other specific types (like M&A, Capital Change, or Director Dealing), the most appropriate fallback category is Regulatory Filings (RNS), as it is the designated catch-all for such announcements distributed through the regulatory feed infrastructure, even when marked as non-regulatory content.
2022-09-21 English
Grant of Share Options
Share Issue/Capital Change Classification · 1% confidence The document is an official announcement disseminated via RNS (Regulatory News Service), indicated by the 'RNS Number' and the footer mentioning RNS as the Primary Information Provider. The content details the 'Grant of Share Options' to employees and amendments to LTIP performance conditions. This type of announcement, concerning insider transactions (though this is options grants, which is closely related to executive compensation/insider activity) or specific corporate actions not covered by major forms like 10-K or ER, often falls under general regulatory announcements. Since it specifically deals with share options granted to employees, it is related to insider dealings or capital structure changes. However, the most fitting category for a general, non-financial results, non-proxy, non-M&A regulatory update distributed via RNS is often the general regulatory filing category, or potentially Director's Dealing (DIRS) if it involved PDMRs, but the text explicitly states 'No PDMR has received options under this award'. Given the nature of announcing option grants and executive compensation scheme adjustments via RNS, and lacking a specific category for 'Share Option Grant', the closest fit among the provided options that covers general corporate news distributed via RNS is 'Regulatory Filings' (RNS) as a fallback, or potentially 'Director's Dealing' (DIRS) if we interpret option grants broadly, but 'RNS' is the most accurate description of the distribution channel and general nature of the filing. Upon review, 'Director's Dealing' (DIRS) is for personal share transactions by directors. This is an option grant under a plan. Since it is a formal announcement via RNS about internal corporate actions (share scheme), and it doesn't fit ER, IR, 10-K, or DIV, the fallback 'RNS' is appropriate. However, let's re-evaluate if any other category fits better. It is not a proxy (PSI), not a dividend (DIV), not a major shareholding change (MRQ). It is a corporate action related to employee compensation/equity. Given the options, 'RNS' (Regulatory Filings) is the safest general classification for this type of RNS announcement.
2022-09-14 English
Trading Update and FY2023 Guidance
Earnings Release Classification · 1% confidence The document is identified by the RNS Number header and contains a 'Trading Update and FY2023 Guidance'. It provides preliminary financial expectations (EBITDA profits, revenues) for the year ended 30 September 2022 and guidance for FY2023. This content aligns with an initial announcement of periodical financial results, which corresponds to the Earnings Release (ER) definition. Although it contains forward-looking guidance, it is not the comprehensive report (like 10-K or IR). The document length is 4998 characters, which is short, but the content is the update itself, not just an announcement that a report is attached. Therefore, ER is the most appropriate classification. FY 2022
2022-09-01 English
Contract Win
Regulatory Filings Classification · 1% confidence The document is a short announcement (4225 characters) released via RNS (RNS Number: 7872U) on August 4, 2022. It details a specific business event: a contract win for a clinical trial worth over £0.8m. This is not a full financial report (like 10-K or IR), nor is it a management change (MANG) or a dividend notice (DIV). It is a specific, material business update released through the regulatory news service. Since it is a specific announcement of a business event (contract win) and is distributed via RNS, it fits best under the general 'Regulatory Filings' category (RNS) as a material event disclosure, although it could also be argued as a general business update. Given the context of RNS distribution and the nature of the announcement (contract win, not a formal financial report), RNS is the most appropriate general classification for non-standard disclosures.
2022-08-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.